Novartis’s Beovu Launch Clouded By Safety Worries
Beovu Uncertainty Should Benefit Regeneron’s Eylea
Executive Summary
New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.
You may also be interested in...
Panic Not, Say Analysts As Apellis’s Syfovre Launch Is Beset By Retinal Vasculitis Events
The US firm’s Syfovre for geographic atrophy due to age-related macular degeneration was linked with a handful of cases of occlusive retinal vasculitis, according to a letter published by a top retinal society, but most analysts believe there is a reasonable explanation.
Novartis Hopes Eye Drug Beovu Bounces Back After New Approval
Having struggled to allay safety concerns for its use in wet age-related macular degeneration, the Swiss major has faith Beovu's efficacy and less frequent dosing will prove more than a match for established DME rival Eylea and newcomer Vabysmo.
Blow For Novartis Eye Drug Beovu As Studies Stop On Safety Worries
The Swiss giant Novartis has decided to halt the MERLIN, RAVEN and RAPTOR studies of Beovu "in the interests of patient safety" which will make the task of competing with the wet AMD market leader Eylea even tougher.